Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2000
10/31/2000US6140319 Administering an vasopeptidase inhibitor for treating and/or relieving the symptoms of angina pectoris
10/31/2000US6140314 Selective and non-invasive visualization or treatment of vasculature
10/31/2000US6140309 Inhibiting the vasoactive effects of beta-amyloid peptides by exposing vessel to a modifier of superoxide formation prior to exposure of the vessel to a amyloid peptide
10/31/2000US6140067 Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
10/31/2000US6140061 Response regulator
10/31/2000US6140052 Diagnosing and treating cancers by determining the presence or absence in a cell of wild-type adenomatous polyposis coli (apc) or a wild-type downstream protein in the apc transcription regulatory pathway
10/31/2000US6140043 Pharmaceutical composition comprising a protein, peptide or a functionally equivalent molecule
10/31/2000US6139865 Taste-masked microcapsule compositions and methods of manufacture
10/31/2000US6139856 Composition useful for providing one-step surgical preparation and drape
10/31/2000US6139855 An enhancer for the performance of a biological active in a topically applied composition comprising an ionized water including an acid water and a basic water
10/31/2000US6139847 Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
10/31/2000US6139835 Homologous recombination for allogeneic donor cells
10/30/2000CA2306644A1 Eyebrow pencil with agglomerated pigments
10/27/2000CA2306574A1 Methods and compositions for treating age-related behavioral disorders in companion animals
10/26/2000WO2000063699A1 A tenascin-c isoform as a marker for neoplasias
10/26/2000WO2000063441A2 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
10/26/2000WO2000063438A2 Method of classifying a thyroid carcinoma using differential gene expression
10/26/2000WO2000063434A1 MinK-RELATED GENES, FORMATION OF POTASSIUM CHANNELS AND ASSOCIATION WITH CARDIAC ARRHYTHMIA
10/26/2000WO2000063430A1 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy
10/26/2000WO2000063415A1 Dna encoding the human vanilloid receptor vr1
10/26/2000WO2000063406A2 Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
10/26/2000WO2000063393A1 Dsp-8 dual-specificity map kinase phosphatase
10/26/2000WO2000063379A2 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
10/26/2000WO2000063376A1 Adipocyte complement related protein homolog zacrp2
10/26/2000WO2000063371A1 Protease activated receptor 2 variants
10/26/2000WO2000063352A2 Human homologues of fused gene
10/26/2000WO2000063351A2 Carbohydrate-modifying enzymes
10/26/2000WO2000063251A1 Composition and method for modulating dendritic cell-t cell interaction
10/26/2000WO2000063241A2 Methods and compositions for modulating an immune response
10/26/2000WO2000063230A2 49 human secreted proteins
10/26/2000WO2000063212A1 Derivatives of triptolide, and preparation and uses thereof
10/26/2000WO2000062813A2 Cationic peg-lipids and methods of use
10/26/2000WO2000062811A1 Pharmaceutical combination, containing a renin-angiotensin-system inhibitor, especially to be used in conjunction with hormone replacement therapy
10/26/2000WO2000062810A1 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
10/26/2000WO2000062807A1 Diagnosis and treatment of neuroectodermal tumors
10/26/2000WO2000062806A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
10/26/2000WO2000062804A2 Identification of sortase gene
10/26/2000WO2000062781A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
10/26/2000WO2000062780A1 Use of glucosylceramide synthesis inhibitors in therapy
10/26/2000WO2000062779A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy
10/26/2000WO2000062778A1 Cyclic protein tyrosine kinase inhibitors
10/26/2000WO2000062777A1 Methods for treatment of sickle cell anemia
10/26/2000WO2000062769A2 Use of ap-1 activators to treat glaucoma and ocular hypertension
10/26/2000WO2000062765A2 ESTROGEN RECEPTOR-β LIGANDS
10/26/2000WO2000062764A1 Gum pad for delivery of medication to mucosal tissues
10/26/2000WO2000062758A1 A method for improving the half-life of soluble viral-specific ligands on mucosal membranes
10/26/2000WO2000062743A2 Skin care compositions containing combination of skin care actives
10/26/2000WO2000062736A2 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
10/26/2000WO2000062735A2 Treatment of neoplasms with viruses
10/26/2000WO2000062657A2 Improvement of t cell mediated immunity
10/26/2000WO2000062614A1 Therapeutic mixture useful in inhibiting lesion formation after vascular injury
10/26/2000WO2000037061A3 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION
10/26/2000WO2000034294A3 Tumor necrosis factor receptor homologue-1 ('trh1')
10/26/2000WO2000028045A3 Human hydrolase proteins
10/26/2000WO2000026197A9 Novel inhibitors of impdh enzyme
10/26/2000WO2000025808A8 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
10/26/2000WO2000021508A3 Novel therapeutic use of compounds with beta-3-agonist activity
10/26/2000WO2000020357A3 Chemical constructs
10/26/2000WO2000019976A9 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them
10/26/2000WO2000016801A9 Methods of downmodulating the immune response to therapeutic proteins
10/26/2000WO2000006206A9 Compositions and methods for the treatment and diagnosis of cardiovascular disease
10/26/2000WO1999021558A3 Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
10/26/2000DE19918434A1 Storage-stable solid proton pump inhibitor formulation useful e.g. for treating duodenal ulcers, comprises amorphous active agent embedded in auxiliary matrix
10/26/2000DE19918106A1 Transdermal patches containing basic or neutral drug include adhesive (meth)acrylic acid polymer in alkali(ne earth) metal salt form
10/26/2000CA2379105A1 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
10/26/2000CA2370945A1 Method of classifying a thyroid carcinoma using differential gene expression
10/26/2000CA2370884A1 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
10/26/2000CA2370690A1 Cationic peg-lipids and methods of use
10/26/2000CA2370659A1 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
10/26/2000CA2370617A1 Dsp-8 dual-specificity map kinase phosphatase
10/26/2000CA2370602A1 Adipocyte complement related protein homolog zacrp2
10/26/2000CA2370570A1 Dna encoding the human vanilloid receptor vr1
10/26/2000CA2370296A1 Improvement of t cell mediated immunity
10/26/2000CA2370272A1 Protease activated receptor 2 variants
10/26/2000CA2370268A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
10/26/2000CA2370129A1 Methods and compositions for modulating an immune response
10/26/2000CA2370126A1 Estrogen receptor-.beta. ligands
10/26/2000CA2369772A1 A therapeutic mixture useful in inhibiting lesion formation after vascular injury
10/26/2000CA2369762A1 A method for improving the half-life of soluble viral-specific ligands on mucosal membranes
10/26/2000CA2369342A1 Carbohydrate-modifying enzymes
10/26/2000CA2369126A1 Use of ap-1 activators to treat glaucoma and ocular hypertension
10/26/2000CA2369078A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk
10/26/2000CA2365523A1 Identification of sortase gene
10/26/2000CA2364209A1 49 human secreted proteins
10/26/2000CA2363994A1 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy
10/26/2000CA2330231A1 Composition and method for modulating dendritic cell-t cell interaction
10/26/2000CA2330022A1 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
10/25/2000EP1046651A1 Composition and method for modulating dendritic cell-T interaction
10/25/2000EP1045908A2 Human urotensin ii
10/25/2000EP1045897A1 Enzyme catalyzed therapeutic agents
10/25/2000EP1045832A2 Novel urethanes, thio and dithio analogues, the salts thereof, medicaments containing said compounds, use and method for the production thereof
10/25/2000EP1045709A1 Method and device for in-situ formulation of a medicinal solution for parenteral application
10/25/2000EP1045701A1 Methods of using human receptor protein 4-1bb
10/25/2000EP1045697A2 Extension of cellular lifespan, methods and reagents
10/25/2000EP1045696A1 Oral oil sorbing composition
10/25/2000EP1045694A1 Method of increasing bone volume using non-naturally-occurring fp selective agonists
10/25/2000CN1271283A Endothelin antogonist and a renin-angiotensin system inhibitor as a combined preparation
10/25/2000CN1271278A Treatment of conduct disorder
10/25/2000CN1271275A Small particle liposome aerosols for delivery of atni-cancer drugs
10/25/2000CN1057670C Prolonged release preparation and polymers thereof
1 ... 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 ... 1151